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Background: Knowledge on HPV prevalence and genotype distribution in HSIL and ICC is highly essential for the
introduction of an effective vaccination program and appropriate epidemiological monitoring of viral ecology
before and after vaccination in Congo. This study aimed to determine the specific-HPV genotypes in HSIL and ICC
among women in southwestern Congo.
Methods: 125 archival paraffin-embedded biopsy collected between 2008 and 2012 and histologically diagnosed
were investigated. DNA extraction was performed using the phenol/chloroform method. HPV search was performed
by nested-PCR using MY09/MY11 and GP5+/GP6+ consensus primers followed by direct sequencing.
Results: The mean age of participants was 44.3 ± 8.2 years. Overall, HPV prevalence was 89.6% (112/125) with all
high-risk genotypes. HPV-DNA was detected in 81.5% (53/65) of HSIL and 98.3% (59/60) of ICC. HPV 16 the most
common genotype was detected in 47.1% (25/53) of HSIL and 52.5% (31/59) of ICC. Other types identified were:
HPV 33 (22.6%), HPV 18 (15%), HPV 31 (11.3%) and HPV 69 (3.7%) in HSIL, and HPV 33 (28.8%), HPV 18 (11.8%), HPV
31 (5%) and HPV 35 (1.7%) in ICC. Knowing that the ADC accounted for 6.7% (4/60) of ICC cases, HPV 18 was identified
in 25% (1/4) of these cases against 75% (3/4) for HPV 16.
Conclusion: Our study showed that HPV 16, 33, 18 and 31 were the four most common genotypes in women with
HSIL and ICC. These findings indicate that current vaccines against HPV could help to reduce the burden of cervical
cancer in Congo.
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Cervical cancer (CC) is a major public health problem
worldwide. Invasive cervical cancer (ICC) is the third most
common carcinoma among women in the world, repre-
senting 8.8% of all cancers. Worldwide 560,505 new cases
of CC are predicted to occur by 2015. More than 459,616
women aged less than 65 years will be affected. The num-
ber of deaths is estimated at 284 902 women a year with
191,833 women aged less than 65 years [1].
In sub-Saharan Africa (SSA), 34.8 (around 75 141) new
cases of cervical cancer are diagnosed per 100 000 women* Correspondence: m.ennaji@yahoo.fr
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unless otherwise stated.annually, and 22.5 (around 50 233) per 100 000 women
die from the disease [1,2]. Rates of cervical cancer vary
considerably in different sub-regions and are ranked
first or second (after breast cancer) in all individual
SSA countries. Guinea, Zambia, Tanzania, Malawi, and
Mozambique have some of the highest ICC incidence
rates in the world at >50 per100 000 women [2,3].
The Republic of Congo holds also some of the highest
incidence and mortality rates of CC in SSA. The Age-
standardized incidence rate is 25.2 per 100 000 women
(14.2 in the world and 30.6 in Central Africa). The Age-
standardized mortality rate is 13.0 per 100 000 women
each year in the Congo (6.8 in the world and 22.2 in
Central Africa) [4].l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.biomedcentral.com/1471-2458/14/1320Human papillomavirus (HPV) infection has been iden-
tified as the primary cause of CC and the third most
common cause of cancer-related death among women.
HPV-DNA has been found in approximately 100% of CC
cases [5]. Currently more than 150 HPV are well char-
acterized. Thereby, about 40 have a high tropism of
anogenital tract. The International Agency for Research
on Cancer [6] has defined twelve genotypes as high-risk
(HR) oncogenic (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, and 59), One probable oncogenic risk assigned to
genotype 68, and possible oncogenic risk assigned to the
types: HPV 26, 53, 66, 67, 70, 73, 82, 30, 34, 69, 85, and
97. Low-risk (LR) genotypes that cause benign lesions and
warts are (HPV 6, 11, 28, 32, 40, 42, 43, 44, 54, 55, 57, 61,
62, 71, 72, 74, 81, 83, 84, 86, 87, and 89) [1,7,8].
Although, most HPV infections are transient and dis-
appear within 2 years without using any treatment [9],
high-risk HPV types can cause persistent infection and are
significantly associated with high-grade cervical lesions
and cancer [10].
Moreover, two HPV vaccines have been developed, a
bivalent for HPV-16 and HPV-18 and a quadrivalent for
HPV-16, HPV-18, HPV-6 and HPV-11, capable of
protecting in an effective way against an infection caused
by these types [11,12]. Although, these vaccines also
confer significant immunity against other HPV types,
the efficiency of cross-protection is less than 100%
[13,14].
Although the distribution of high-risk types in High-
grade Squamous lesions (HSIL) and ICC shows little vari-
ation among regions of the world, [15-17], perfect
knowledge of these types is essential for the introduction
of an effective vaccination program and for better moni-
toring of viral ecology before and after vaccination in a
less studied population. This information is also needed to
assess the vaccine benefit on cervical cancer prevention in
the population.
Until now, no study has been conducted on this target
population in the Republic of Congo. Thus, the aim of
this study was to determine the prevalence and the HPV
type’s distribution in HSIL and ICC among Congolese
women in the southwestern part of the country.
Methods
Sample collection
One hundred and thirty six formalin-fixed paraffin-
embedded (FFPE) biopsy samples collected between
2008 and 2012 where HSIL and ICC diagnosis has been
indicated were anonymously selected from tumor Registry
files of Histopathological Unit of General Hospital of
Loandjili (GHL) in Pointe-Noire. Altogether only 125
(91.9%) archival FFPE samples were found, 65 HSIL and
60 ICC (including 56 invasive squamous cell carcinomas
(SCC) and 4 adenocarcinoma (ADC)) from women aged28-74 years (mean age: 44.3 ± 8.2 years). The mention of
diagnosis and especially the availability of biopsy to the
laboratory were the two major inclusion criteria. For
the purposes of scientific research, the study was approved
by the local ethics committee in the Health Sciences
(Comité d’éthique de la Recherche en Sciences de la Santé,
CERSSA) with an exemption from requiring consent from
patients (study was carried out on archival material to be
destroyed after a certain preservation time).
DNA extraction
Three to five sections of FFPE tissue were cut on a
microtome and deparaffinized with xylenes and washed
with 70% ethanol at ambient temperature. DNA extraction
was performed using the manual technique of phenol/
chloroform used in the laboratory of Virology, Microbiol-
ogy and Quality/Eco-toxicology and Biodiversity (LVMQ/
ETB) of the Faculty of Sciences and Techniques, University
Hassan II Mohammedia-Casablanca in Morocco after
enzymatic treatment with proteinase K. The DNA was
precipitated with 2/5 volumes of 7.4M ammonium acet-
ate and 2 volumes of 100% ethanol. DNA pellet was subse-
quently washed with 70% ethanol, air-dried and then
suspended again in 30 or 50mL of Ultra-pure PCR water
nuclease-free (Bioline, UK), thereafter stored at 20°C until
further use.
HPV-DNA detection and genotyping
After extraction, DNA concentration was evaluated in
NanoDrop 8000 Spectrophotometer (Nanodrop Technolo-
gies, Wilmington, DE, USA). A 268-base-pair fragment of
the housekeeping β-globin gene was amplified using the
GH20/PCO4 primer set to evaluate quality and integrity
of DNA extract as previously described [18]. All amplifi-
cations were carried out with 100ng/μL of DNA concen-
tration in a Perkin Elmer 2400 GeneAmp PCR thermal
Cycler (Scientific Support, Inc, Hayward, CA). DNA from
the SiHa cell line was used as positive PCR control and
Ultra-pure PCR water nuclease-free (Bioline, UK) as nega-
tive PCR control.
The samples were analyzed for HPV-DNA detection
by nested-PCR using two consensus primer sets, i.e.,
MY09/MY11 and GP5/GP6 as previously described [19].
To avoid contamination leading to false positive results,
both PCR round were performed in separate room. All
primer sequences are given in Table 1. Amplified PCR
product was analyzed on 2% agarose gel, stained with eth-
idium bromide and visualized under UV light. The PCR
products were identified on the basis of their predicted
fragment size. HPV typing was performed at the Mo-
lecular Biology and Functional Genomics platform of
Support Unit Scientific Research and Technology, National
Centre for Scientific and Technical Research of Rabat
(UATRS-CNRST, Rabat, Morocco). Direct sequencing was
Table 1 Primers used for HPV detection and typing in this study
Primers Sequences (5’ to 3’) Target gene Amplicons length Ref
GH2O GAA GAG CCA AGG ACA GGT AC b-Globin 268pb Resnick et al., 1990 [18]
PCO4 CAA CTT CAT CCA CGT TCA CC
MYI 1 GCM CAG GGW CAT AAY AAT GG L1 450pb Lee et al. 2009 [19]
MYO9 CGT CCM ARR GGA WAC TGA TC
GP5+ TTT GTT ACT GTG GTA GAT ACT AC L1 142pb
GP6+ GAA AAA TAA ACT GTA AAT CAT ATT C
M = A + C, R = A + G, W = A + T, Y = C + T
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BigDye Terminator v3.1 Cycle Sequencing Kit (PE/Applied
Biosystems, Foster City, CA, USA) using the GP6+ anti-
sense as primer. Purification of PCR products were car-
ried out with the ExoSAP-IT® clean up system (USB
Corporation, Cleveland, USA) whereas, the sequencing
products was done with a Sephadex column 50G (Phar-
macia Biotech Co., Ltd, Uppsala Sweden). Electrophoresis
migration was performed in a 16 capillary automated se-
quencer 3131XL/Genetic HITACHI Analyzer (PE/Applied
Biosystems, Foster City, CA, USA) at a constant voltage of
12 KV.
The DNA sequences were aligned by Molecular Evolu-
tionary Genetics Analysis (MEGA) software Version 4.0
(http://www.megasoftware.net) and results were analyzed
using the BLAST algorithm (http://www.ncbi.nih.gov/
BLAST). For each typing, we searched the hypervariable
region from 34 to 50 bp downstream of the GP5+ bind-
ing site (Figure 1) able to accurately identify any HPV
genotypes as described previously [19]. An identity of
90% or more with the sequences of the GenBank data-
base (NCBI, national Institute of Health, Bethesda, MD,
USA) was retained to confirm every type of HPV ob-
tained. The Nucleotide sequences data set supportingFigure 1 Sequencing data of HPV genotypes: An example of electrop
Alignment Search (BLAST) analysis result. Electrophoregram pointing th
downstream of the binding site of GP5+ primer (underlined in green, readthe results of this article was included within the article
as additional file published through the LabArchives
database (DIO “10.6070/H4PZ56TF”).Results
Overall HPV DNA prevalence
Detection of HPV DNA was performed in tumor samples
of 125 Congolese women with HSIL or ICC histologically
diagnosed. Overall, DNA was successfully amplified in all
of the 125 (100%) samples tested (β-globin PCR). Our re-
sults showed that 112/125 (89.6%) of the total samples
were positive for HPV-DNA. HPV-DNA was detected in
81.5% (53/65) of HSIL and 98.3% (59/60) of ICC (98.2% of
SCC and 100% of ADC respectively).HPV type-specific prevalence
Six different genotypes have been identified, all were
oncogenic high-risk types. HPV 16 the most common
was detected in 47.1% (25/53, 95%IC: 34.4-60.3) of HSIL
and 52.5% (31/59, 95%IC: 40.0-64.7) of ICC. Other types
identified were in decreasing frequency: HPV 33 (22.6%,
95%IC: 13.4-35.5), HPV 18 (15%, 95%IC: 7.8-27.0), HPV
31 (11.3%) and HPV 69 (3.7%) in HSIL; HPV 33 (28.8%,horegram sequence from HPV type 16 and its Basic Local
e hyper variable region (underlined in red) of HPV L1 gene,
ing direction: from right to left).
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31 (5%) and HPV 35 (1.7%) in ICC.
Knowing that the ADC accounted for 6.7% (4/59) of
positive ICC cases, only 1 of out 4 (1.7%) of them was
identified as HPV 18 against 3 of out 4 (5%) for HPV 16.
All the results are reported in Table 2 and Figure 2.
The five most common individual oncogenic HPV types
found in ICC in our study were compared with profiles
found in the World, African regions; Europe and North
America according to the WHO/ICO HPV information
center (Table 3).Discussion
The study reported here is the first of its kind among
Congolese women with high-grade lesions and invasive
cervical cancer in the aim of understanding the HPV
prevalence and genotypes distribution in this target popu-
lation groups in the southwestern part of the Country.
Study was conducted retrospectively, using FFPE biopsies
diagnosed as HSIL or ICC taken from 2008 to 2012, from
GHL in Pointe-Noire. The GHL is the only hospital of
south of the country to have a pathological laboratory.
The Patients received in this laboratory come from differ-
ent regions of the country and represents wide social and
economic strata. Therefore, the results of our study could
have particular interest in the area.
Worldwide, HPV prevalence in cervical cancer is re-
ported to be 99.7% [5]. This prevalence is average 84.9%
in HSIL and 87.2% in invasive cervical carcinoma [20].
In our study, 89.6% of the samples in general were HPV
positive, of which 81.5% in HSIL and 98.3% in ICC. This
findings corroborating with the literature data as reported
in several countries especially in Africa where the preva-
lence is very high. Indeed, it was reported an average
prevalence in Africa 85.1% and 93.9% in HSIL and ICC,
respectively, with slight differences depending on the
country [2,21]. Some countries such as Senegal, South
Africa and Kenya have a prevalence of 80.9%, 88.4%
and 96.6% in HSIL respectively. Mozambique, Kenya,
and Morocco for their part have a prevalence of HPV
infection in the ICC of the order of 97.7%, 96.9% and
94.7% respectively [22,23]. But also in Europe [24], asTable 2 Type-specific HPV and their distribution in paraffin-e
Congolese women, 2008–201
Histological types All HPV+
n(%) 16 95% IC 33 9
HSIL (n = 65) 53(81.5) 25(47.1) 34.4-60.3 12(22.6) 1
ICC (n = 60) 59(98.3) 31 (52.5) 40.0-64.7 17(28.8) 1
SCC (n = 56) 55(98.2) 28 (50.9) 38.0-63.6 17(30.9) 2
ADC (n = 4) 4(100) 3(75.0) 30.0-95.4 0
95% CI = confidence interval for the four most common genotypes identified.shown a recent study in Italy reported a 96.0% rate of
HPV positivity in the ICC [25].
In our study, HPV 16 was the most common genotype
found in HSIL (47.1%) and ICC (52.5%). These findings
let appear a very high proportion of the infection by this
genotype in our study population and are in keeping
with other studies in the world [26-28]. These data show
that infection with HPV 16 is a great risk of cancer de-
velopment and particular attention should be devoted to
these cases [29,30].
We found also HPV 33 was the second most common
types in HSIL (22.6%) and ICC (28.8%) followed by
HPV18, 15% and 11.8%; HPV31, 11.3% and 5% in HSIL
and ICC respectively. This profile although slightly
different from those reported in sub-Saharan Africa
[20,31,32], generally reflects the global distribution pattern
of HPV in Africa in some meta-analysis studies [16,33].
The type-specific distribution of HPV in799 cervical can-
cer biopsies from Africa showed that HPV 16 accounted
for 50.2% of samples, HPV 18 for 14.1%, and HPV 45 for
7.9% [34]. The cumulative prevalence of HPV 16/18 in
our study was 62.1% (47.1%/15%) and 64.3% (52.5%/
11.7%) in HSIL and ICC respectively. Our results are
lower than the global average which is 70% for both types
[26,27]. However, these results confirm the low prevalence
of these two types combined in Africa compared to other
regions of the world [16,28].
In his study of women with HIV in Pointe-noire,
Alidjinou using the Hybrid Capture II (HC2) method had
found a prevalence of 70.9% of combined HPV16/18/45
[35]. Knowing that the probe (probe HC2 16/18/45) used
by the latter allowed only to make a global typing, these
proportions would be comparable to ours if he had used a
specific genotyping method especially as we have not
found any HPV 45 in our study. However ours findings
while corroborating with those reported in the literature
shows that current prophylactic vaccines against HPV
would play a significant role in reducing the burden of
cervical cancer in Congo.
In addition, although often diagnosed in the ADC, on
4 cases of our study, only a case was positive by HPV 18.
This result indicates that the genotype 16 remains
dominant whatever the histological type of the cancer.mbedded biopsy specimens of HSIL and ICC cases from
HPV genotypes n (%)
5% IC 18 95% IC 31 95.1C 69 35
3.4-35.5 8(15.0) 7.8-27.0 6(113) 5.3-22.6 2(3.7) 0
8.8.41.4 7(11.8) 5.8-22.5 3(5.0) 1.7-13.9 0 1(1.7)
0.3-44.0 6(10.7) 5.0-21.8 3(5.3) 1.8-14.8 0 1(1.8)
1(25.0) 4.5-69.9 0 0 0
Figure 2 HPV genotypes frequencies in HSIL and ICC among women from southwestern Congo.
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cervical cancer in the world, we found in our study a
very high rate of HPV 33 in both HSIL (22.6%) than in
ICC (28.8%), making it the second most prevalent type
in our study population. This trend was also found with
HPV 31 with frequencies of 11.3% and 5% in HSIL and
ICC respectively. Admittedly lower degree, the high fre-
quencies of these two types has been reported in several
studies in Europe [17,36]. In our study, these results could
be explained by the fact that the study area is open to a
significant population mixing related to the industrial and
oil activities. In the literature, it is reported the high pro-
portion of 4% to 6% [17,37] of HPV35 in the ICC cases in
SSA compared to another region in the world where the
proportion is lower, ranging from 1% to 3% [16,21]. In our
study, 1 out of 60 cases was identified HPV-35 positive.
Further studies with a larger sample are needed to assess
the importance of this type in our population especially
with the viral ecological change due to the vaccination
against HPV 16/18. We also report the identification ofTable 3 The five most common HPV types among Congolese





1st HPV16 (52.5%) HPV16 (56.7%) HPV16 (58.5%) HP
2nd HPV33 (28.8%) HPV18 (15.9%) NPV18 (19.9%) HP
3nd HPV18 (11.8%) HPV33 (4.6%) HPV45 (8.0%) H
4th HPV31 (5.0%) HPV45 (4.5%) HPV31 (2.5%) H
5th HPV35 (1.7%) HPV58 (4.4%) HPV33 (2.4%) H
(a) Data for Congo: present study.
(b) Source of information: WHO/ICO Information Centre on Human Papillomavirus (HPV 69 (3.7%) in a relatively high proportion in HSIL but
absent in the ICC. Although classified in the possible
probable high risk types [1], its high proportion could
reflect its oncogenic potential in cervix. An epidemiological
surveillance would be necessary for this kind of genotype
in our population after the introduction of vaccination
against type 16 and 16.
In sum, the pattern of distribution of HPV in HSIL and
ICC in southwestern Congo is as follows: HPV16, HPV33,
HPV18, HPV31, HPV69 and HPV35. Note the notable ab-
sence of HPV45 which is among the five frequently identi-
fied worldwide genotypes. Our study showed for the
first time a high prevalence of HPV in HSIL and ICC in
women attending GHL in Congo. Early detection of in-
fection for high-risk types could give physicians the
possibility of more effective management of the disease
[38]. This study has also shown the distribution of HPV
genotype in HSIL and ICC, reflecting the local epidemi-
ology of HPV transmission in southwestern Congo popu-
lations. Thus; the burden of cervical cancer in our countrywomen with invasive cervical cancer in Southwestern
orth America
Africab Europab North
Americabuth Africa Western Africa
V16 (52.1%) HPV16 (40.5%) HPV16 (58.8%) HPV16 (54.6%)
V18 (10.7%) HPV45 (13.7%) HPV18 (16.3%) HPV18 (17.1%)
PV33 (9.1%) HPV18 (10.9%) HPV33 (4.4%) HPV31 (5.3%)
PV31 (4.3%) HPV58 (3.9%) HPV45 (4.1%) HPV45 (4.7%)
PV45 (3.3%) HPV33 (3.2%) HPV31 (4.1%) HPV33 (3.6%)
HPV) and Cervical Cancer [39].
Boumba et al. BMC Public Health 2014, 14:1320 Page 6 of 7
http://www.biomedcentral.com/1471-2458/14/1320must be supported by the implementation of primary
prevention through vaccination but also a real organized
cytology screening program.
Conclusion
The findings of this study are very significant because
they provide, for the first time, baseline information on
the HPV type’s distribution in HSIL and ICC in the Re-
public of Congo, which may guide the development of CC
prevention and control programs in the country. These
findings also indicate that HPV vaccination might be
beneficial among Congolese population.
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